US SEC Trading Suspension Halt Orders — October 01, 2026

The NYSE immediately suspended Class A shares and the stock began trading on OTC Pink Limited Market under GETY on September 30, 2026 after the company elected not to appeal the delisting proceedings

Nasdaq determined that Lantern failed to maintain the $35 million minimum market value of listed securities for 30 consecutive business days; the company has until March 24, 2027 to regain compliance

GXAI failed the Nasdaq $1.00 minimum closing bid requirement during August 14-September 25, 2026, creating a direct delisting risk unless it achieves at least $1.00 for 10 consecutive business days

The death of independent director Efrat L. Greenstein Brayer caused SKYX to fall below Nasdaq requirements for a majority-independent board and a three-member audit committee

Shareholders approved the Brookfield Bancshares merger by 3,762,060 votes to 3,905 against, representing 71.69% of outstanding shares; the transaction closed October 1, 2026

NSTS shareholders received $14.31 per share in cash, with approximately $73.7 million of total consideration, providing a defined realized-value outcome rather than continued public-market exposure

NXDR will voluntarily withdraw from the NYSE at market close on October 13 and begin trading on Nasdaq at market open October 14 under the same ticker, limiting ticker-transition risk

Getty has already lost NYSE trading and moved to OTC, whereas Lantern and Gaxos.ai remain in cure periods and SKYX has no immediate listing suspension; regulatory urgency is therefore highest for Getty, followed by Lantern and Gaxos.ai

Gaxos.ai may receive an additional 180-day compliance period if it satisfies the remaining Nasdaq requirements and submits its intent to cure, while Lantern's filing identifies a 180-day period through March 24, 2027

None of the six filings reports insider purchases or sales, dividends, buybacks, splits, earnings guidance, revenue, margins, or leverage trends; investors should not infer operating improvement or management conviction from the regulatory filings alone [NEUTRAL/INFORMATION GAP]

The company provides no assurance that GETY will continue trading OTC, that broker-dealers will provide public quotes, or that sufficient volume will exist for an efficient market

The NYSE cited abnormally low selling-price levels, while the board postponed the October 8 annual meeting to evaluate strategic financing alternatives and balance-sheet initiatives with debt and equity holders

Failure to restore listed-securities market value above the $35 million threshold by March 24, 2027 could result in Nasdaq Capital Market delisting

Management may consider a reverse stock split to address the $1.00 bid-price deficiency, creating potential dilution, volatility, and corporate-action risk for existing holders

If the initial cure period and any additional 180-day period fail, Nasdaq may issue a delisting determination subject to appeal to a Hearings Panel

SKYX is currently out of compliance with Nasdaq Rules 5605(b)(1) and 5605(c)(2)(A); failure to appoint an adequate independent director and audit committee could threaten its listing

NSTS ceased to exist as a separate entity, its stock was delisted, and its directors and executive officers ceased serving at the merger effective time; there is no continuing public-equity investment opportunity

The NYSE-to-Nasdaq move may create temporary liquidity, index, broker-routing, and operational volatility around October 13-14 despite the ticker remaining NXDR

None of the six filings includes period-over-period revenue, margin, earnings, leverage, insider, dividend, or buyback information, preventing confirmation of whether listing problems reflect improving or deteriorating operating fundamentals

The October 1 completion and $14.31-per-share cash consideration create a fully specified transaction closeout; investors holding the security should verify cash settlement and remove the position from ongoing public-equity screens

NXDR's scheduled Nasdaq debut on October 14 under the unchanged ticker offers a defined event window for monitoring liquidity, spreads, volume, and any exchange-related technical dislocations

Lantern has until March 24, 2027 to restore compliance, creating a speculative turnaround setup if the company can increase market value without excessive dilution; position sizing should reflect delisting risk

GXAI could avoid delisting by reaching at least $1.00 for 10 consecutive business days, making sustained bid-price recovery the key measurable catalyst through March 29, 2027

Eligibility for a second 180-day period could extend the company's listed-market runway beyond the initial March 29, 2027 deadline, subject to satisfying all other continued-listing requirements

Appointment of a qualified independent director and restoration of a three-member audit committee could remove the Nasdaq deficiency before the earlier of the next annual meeting or the applicable cure deadline

The postponed annual meeting and evaluation of financing alternatives could produce a material restructuring, financing, or balance-sheet announcement, although any opportunity is offset by severe OTC liquidity and dilution risks

Lantern, Gaxos.ai, and SKYX retain exchange trading while Getty has already moved OTC; investors seeking regulatory-recovery exposure may prefer the names with measurable cure paths over the completed Getty delisting

Four of the six filings involve active or completed listing-status actions affecting Nasdaq or NYSE trading: Lantern's market-value deficiency, Gaxos.ai's bid-price deficiency, Getty's NYSE suspension and delisting, and SKYX's governance deficiency. The dominant portfolio theme is regulatory eligibility rather than operating performance.

The filings span a full severity ladder: NSTS completed a merger and ceased to exist; Nextdoor is executing a voluntary exchange transfer; Lantern and Gaxos.ai remain in cure periods; SKYX has no immediate listing effect; and Getty has already moved to OTC trading. This makes regulatory stage a more important differentiator than company sector.

Three companies retain remediation pathways, with deadlines ranging from March 24, 2027 for Lantern to March 29, 2027 for Gaxos.ai and as late as September 26, 2027 for SKYX depending on the annual-meeting date. Getty has no appeal plan, while NSTS's delisting is final because the company ceased to exist independently.

Getty's OTC migration explicitly carries uncertainty around public quotations and trading volume, while Nextdoor's exchange transfer creates a near-term venue transition. Investors should expect wider spreads and execution risk in regulatory-event names even when the underlying corporate action is not economically negative.

Across all six filings, the supplied data contains no comparable revenue, margin, earnings, leverage, capital-allocation, insider-trading, or guidance metrics. Any portfolio-level claim about growth or profitability would be unsupported; regulatory status and event timing are the principal observable signals.

SKYX demonstrates that the loss of a single independent director can create a Nasdaq deficiency even without an immediate suspension. Board composition and audit-committee requirements should be monitored alongside financial listing thresholds.

Monitor the NYSE withdrawal at market close on October 13, 2026 and Nasdaq trading commencement at market open on October 14, 2026, including volume, spreads, and any ticker-routing issues.

Monitor GETY's OTC Pink quotation continuity, broker-dealer support, trading volume, and any strategic financing or balance-sheet announcement following the postponed annual meeting.

The 2026 annual meeting, previously scheduled for October 8, 2026, has been postponed; a rescheduled date may provide information on financing, debt-holder negotiations, and governance.

Track actions to restore the $35 million MVLS requirement before March 24, 2027, including capital raises, equity-price recovery, dilution, or any Nasdaq determination.

Monitor whether GXAI achieves a closing bid of at least $1.00 for 10 consecutive business days before March 29, 2027 and whether management announces a reverse split.

Watch for a written request and Nasdaq decision regarding a possible additional 180-day cure period after the initial deadline, contingent on satisfying other listing standards.

Monitor appointment of a replacement independent director and reconstitution of the three-member audit committee by the earlier of the next annual meeting or September 26, 2027; if the meeting occurs earlier, the relevant deadline may be March 25, 2027.

Confirm receipt of the $14.31-per-share cash merger consideration and removal of NSTS from active trading and portfolio monitoring following the October 1, 2026 effective time.